Welcome to our dedicated page for Gt Biopharma news (Ticker: GTBP), a resource for investors and traders seeking the latest updates and insights on Gt Biopharma stock.
GT Biopharma develops clinical-stage immuno-oncology therapeutics based on its proprietary TriKE® natural killer cell engager platform. News around GTBP focuses on candidate-specific development updates for GTB-3650, a TriKE® program for relapsed or refractory CD33-expressing hematologic malignancies, and GTB-5550, a B7-H3-targeted TriKE® program for solid tumors known to express B7-H3.
Company updates also cover FDA investigational new drug activity, Phase 1 trial enrollment and safety-review disclosures, R&D spending, liquidity commentary and periodic financial results. GT Biopharma also issues investor-conference announcements as it presents its NK cell engager strategy and clinical pipeline to the capital markets.
GT Biopharma (NASDAQ: GTBP) reported its Q1 2024 financial results and provided a corporate update. Key highlights include the anticipated IND clearance for GTB-3650, a nanobody TriKE® for CD33+ leukemia in Q2 2024, and Phase 1 trial initiation in 2H 2024. The company also expects to submit an IND for GTB-5550 in Q4 2024, targeting B7H3-positive solid tumors, with a Phase 1 trial planned for early 2025. GT Biopharma reported $9.81 million in cash as of March 31, 2024, enough to fund operations into 2025. R&D expenses decreased significantly to $777,000 from $1.65 million YoY, while SG&A expenses rose to $2.31 million from $2.02 million YoY. Net loss widened to $2.27 million from $227,000 in Q1 2023.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.